Mineralys Therapeutics Statistics
Total Valuation
MLYS has a market cap or net worth of $898.63 million. The enterprise value is $700.45 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MLYS has 64.74 million shares outstanding. The number of shares has increased by 34.13% in one year.
| Current Share Class | 64.74M |
| Shares Outstanding | 64.74M |
| Shares Change (YoY) | +34.13% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | 1.89% |
| Owned by Institutions (%) | 51.34% |
| Float | 43.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.62 |
| P/TBV Ratio | 4.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.02
| Current Ratio | 14.02 |
| Quick Ratio | 13.53 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -82.24% and return on invested capital (ROIC) is -55.62%.
| Return on Equity (ROE) | -82.24% |
| Return on Assets (ROA) | -52.56% |
| Return on Invested Capital (ROIC) | -55.62% |
| Return on Capital Employed (ROCE) | -100.60% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.49M |
| Employee Count | 51 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.69% in the last 52 weeks. The beta is -0.39, so MLYS's price volatility has been lower than the market average.
| Beta (5Y) | -0.39 |
| 52-Week Price Change | +6.69% |
| 50-Day Moving Average | 12.28 |
| 200-Day Moving Average | 12.29 |
| Relative Strength Index (RSI) | 52.68 |
| Average Volume (20 Days) | 1,374,655 |
Short Selling Information
The latest short interest is 4.71 million, so 7.27% of the outstanding shares have been sold short.
| Short Interest | 4.71M |
| Short Previous Month | 2.22M |
| Short % of Shares Out | 7.27% |
| Short % of Float | 10.94% |
| Short Ratio (days to cover) | 2.39 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -192.40M |
| Pretax Income | -90.80M |
| Net Income | -177.81M |
| EBITDA | -192.36M |
| EBIT | -192.40M |
| Earnings Per Share (EPS) | -$3.66 |
Full Income StatementBalance Sheet
The company has $198.19 million in cash and n/a in debt, giving a net cash position of $198.19 million or $3.06 per share.
| Cash & Cash Equivalents | 198.19M |
| Total Debt | n/a |
| Net Cash | 198.19M |
| Net Cash Per Share | $3.06 |
| Equity (Book Value) | 191.26M |
| Book Value Per Share | 3.84 |
| Working Capital | 190.71M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$166.31 million and capital expenditures -$96,000, giving a free cash flow of -$166.41 million.
| Operating Cash Flow | -166.31M |
| Capital Expenditures | -96,000 |
| Free Cash Flow | -166.41M |
| FCF Per Share | -$2.57 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |